Nuantic AG
AI-guided optimization of biologics.
97% of all drug development projects fail before or during clinical trials. Especially for biologics, failures related to suboptimal candidates like insufficient potency, immunogenicity, toxic side effects or poor drug-like properties are the dominant cause of failure. Latentfusion.ai provides AI-guided lead optimization to biotech companies seeking to increase their chances to overcome these hurdles and bring therapeutics to the market. We employ smart, highly efficient protein design algorithms to help to unlock innovative therapies, alleviate patient burden and reduce drug prices.
The founding team currently consists of CEO Elias Hagmann (electrical engineer ETH, 12+ years of biotech industry experience) and CSO Dieter Schiegg (biochemist UZH, 13+ years of biotech industry experience).
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Nuantic AG
AI-guided optimization of biologics.
Headquarter:
Zürich
Foundation Date:
December 2025
Technology:
- Biotech
Sectors:
- Biotech
- Diagnostics
- Drug development platforms
- Drug discovery
- Machine Learning / AI
- Protein drugs
Support received
